{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:14:50Z","timestamp":1794863690404,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was partially supported by the Italian Ministry of Health (Institutional Funding Ricerca Corrente) IRCCS San Raffaele Roma."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fremanezumab has demonstrated to be effective, safe, and tolerated in the prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials (RCTs). Real-life studies are needed to explore drug effects in unselected patients in routine circumstances and to provide higher generalizability results. This study explores the effectiveness, safety, and tolerability of fremanezumab in a real-life population of individuals affected by high-frequency episodic (HFEM: 8\u201314\u00a0days\/month) or CM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a 12-week multicenter, prospective, cohort, real-life study. We considered all consecutive patients affected by HFEM or CM visited at 9 Italian headache centers from 28\/07\/2020 to 11\/11\/2020. Eligible patients were given subcutaneous fremanezumab at the doses of 225\u00a0mg monthly or 675\u00a0mg quarterly, according to their preference. Primary study endpoints were the change in monthly migraine days (MMDs) in HFEM and monthly headache days (MHDs) in CM patients at weeks 9\u201312 compared to baseline. Secondary endpoints encompassed variation in monthly analgesic intake (MAI), Numerical Rating Scale (NRS), HIT-6 and MIDAS scores, and\u2009\u2265\u200950%,\u2009\u2265\u200975% and 100% responder rates at the same time intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-seventh number migraine patients had received\u2009\u2265\u20091 subcutaneous fremanezumab dose and were considered for safety analysis, while 53 patients completed 12\u00a0weeks of treatment and were included also in the effectiveness analysis. Fremanezumab was effective in both HFEM and CM, inducing at week 12 a significant reduction in MMDs (-4.6,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), MHDs (-9.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), MAI (-5.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05; -11.1,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;\u20090.001), NRS (-3.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; -2.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and MIDAS scores (-58.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05; -43.7;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). HIT-6 was significantly reduced only in HFEM patients (-18.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Remission from CM to episodic migraine and from MO to no-MO occurred in 75% and 67.7% of the patients. The\u2009\u2265\u200950%,\u2009\u2265\u200975% and 100% responder rates at week 12 were 76.5%, 29.4% and 9.9% in HFEM and 58.3%, 25% and 0% in CM. Younger age emerged as a positive response predictor (OR\u2009=\u20090.91; 95% CI 0.85\u20130.98,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013). Treatment-emergent adverse events were uncommon (5.7%) and mild. No patient discontinued fremanezumab for any reason.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fremanezumab seems more effective in real-life than in RCTs. Younger age emerges as a potential response predictor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-022-01396-x","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T05:02:29Z","timestamp":1649480549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5670-3755","authenticated-orcid":false,"given":"Piero","family":"Barbanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Egeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Aurilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florindo","family":"d\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Di Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the FRIEND-Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"issue":"19","key":"1396_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Engl J Med 383(19):1866\u20131876","journal-title":"N Engl J Med"},{"issue":"4","key":"1396_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ncl.2019.07.004","volume":"37","author":"SK Parikh","year":"2019","unstructured":"Parikh SK, Silberstein SD (2019) Preventive Treatment for Episodic Migraine. Neurol Clin 37(4):753\u2013770. https:\/\/doi.org\/10.1016\/j.ncl.2019.07.004 (Epub 2019 Aug 22)","journal-title":"Neurol Clin"},{"issue":"Suppl 2","key":"1396_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/head.12505_2","volume":"55","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Silberstein SD (2015) Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache 55(Suppl 2):103\u2013122","journal-title":"Headache"},{"issue":"1","key":"1396_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","volume":"20","author":"EC Agostoni","year":"2019","unstructured":"Agostoni EC et al (2019) Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain 20(1):92. https:\/\/doi.org\/10.1186\/s10194-019-1038-4","journal-title":"J Headache Pain"},{"key":"1396_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.105900","volume":"195","author":"YW Alasad","year":"2020","unstructured":"Alasad YW, Asha MZ (2020) Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis. Clin Neurol Neurosurg 195:105900. https:\/\/doi.org\/10.1016\/j.clineuro.2020.105900 (Epub 2020 May)","journal-title":"Clin Neurol Neurosurg"},{"issue":"17","key":"1396_CR6","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s40265-018-1004-5","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM (2018) Fremanezumab: First Global Approval. Drugs 78(17):1829\u20131834. https:\/\/doi.org\/10.1007\/s40265-018-1004-5","journal-title":"Drugs"},{"issue":"19","key":"1396_CR7","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999\u20132008","journal-title":"JAMA"},{"issue":"22","key":"1396_CR8","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122","journal-title":"N Engl J Med"},{"issue":"10203","key":"1396_CR9","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M, Janka L, Ashina M (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030\u20131040","journal-title":"Lancet"},{"issue":"18","key":"1396_CR10","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, Dodick DW (2020) Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology 95(18):e2487\u2013e2499. https:\/\/doi.org\/10.1212\/WNL.0000000000010600 (Epub 2020 Sep 10)","journal-title":"Neurology"},{"issue":"2","key":"1396_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.pupt.2014.01.005","volume":"27","author":"S Saturni","year":"2014","unstructured":"Saturni S, Bellini F, Braido F, Paggiaro P, Sanduzzi A, Scichilone N, Santus PA, Morandi L, Papi A (2014) Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther 27(2):129\u201338","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"1396_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, Filippi M, Frediani F, Bono F, Grazzi L, Salerno A, Mercuri B, Carnevale A, Altamura C, Vernieri F (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61(2):363\u2013372","journal-title":"Headache"},{"key":"1396_CR13","doi-asserted-by":"crossref","unstructured":"Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D\u2019Amico D, Filippi M, Altamura C, Vernieri F (2021) EARLY Study Group. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache 61(9):1351\u20131363","DOI":"10.1111\/head.14194"},{"key":"1396_CR14","doi-asserted-by":"publisher","unstructured":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d\u2019Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P (2021) GARLIT Study Group. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 3:221\u201335. https:\/\/doi.org\/10.1186\/s10194-021-01247-1","DOI":"10.1186\/s10194-021-01247-1"},{"key":"1396_CR15","unstructured":"Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, Quintana S, Cevoli S, Favoni V, d\u2019Onofrio F, Egeo G, Rao R, Filippi M, Barbanti P, Altamura C. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain, in press."},{"key":"1396_CR16","doi-asserted-by":"crossref","unstructured":"Cohen JM, Thompson S, Patterson-Lomba O, Driessen MT, Seminerio M, Carr K, Mu F. US real-world reductions in migraine and headache days for patients with chronic and episodic migraine initiating fremanezumab. Abstract. Presented at the 2021 American Academy of Neurology Annual Meeting.","DOI":"10.1212\/WNL.96.15_supplement.4171"},{"key":"1396_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629\u2013808","journal-title":"Cephalalgia"},{"key":"1396_CR18","doi-asserted-by":"crossref","unstructured":"Gazzetta Ufficiale n.182, 21\u20137\u20132020","DOI":"10.1038\/s41583-020-0282-6"},{"key":"1396_CR19","unstructured":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Lovati C, Bertuzzo D, d\u2019Onofrio F, Doretti A, Di Fiore P, Finocchi C, Schiano Di Cola F, Ranieri A, Colombo B, Bono F, Albanese M, Cevoli S, Barbanti P for the GARLIT Study Group. Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. European Journal of Neurology, in press."},{"issue":"10161","key":"1396_CR20","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Hours-Zesiger P, Ferrari MD, Klatt J (2018) Efficacy and tolerability of erenumab in episodic migraine patients who previously failed 2\u20134 preventive treatments: a randomised placebo-controlled phase 3b study. Lancet 392(10161):2280\u20132287","journal-title":"Lancet"},{"issue":"10","key":"1396_CR21","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, Lainez MJA et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814\u2013825. https:\/\/doi.org\/10.1016\/S1474-4422(20)30279-9","journal-title":"Lancet Neurol"},{"key":"1396_CR22","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","volume":"81","author":"E Cernuda-Morollon","year":"2013","unstructured":"Cernuda-Morollon E, Larrosa D, Ram\u00f2n C, Vega J, Mart\u00ednez-Camblor P, Pascual J (2013) Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 81:1191\u20131196","journal-title":"Neurology"},{"issue":"7","key":"1396_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/11534920-000000000-00000","volume":"24","author":"PL Durham","year":"2010","unstructured":"Durham PL, Vause CV (2010) Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs 24(7):539\u2013548","journal-title":"CNS Drugs"},{"issue":"12","key":"1396_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/j.1468-1331.2008.02343.x","volume":"15","author":"M Sch\u00fcrks","year":"2008","unstructured":"Sch\u00fcrks M, Diener HC (2008) Migraine, allodynia, and implications for treatment. Eur J Neurol 15(12):1279\u20131285","journal-title":"Eur J Neurol"},{"issue":"7","key":"1396_CR25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1177\/0333102418825346","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Reed ML, Fanning KM, Munjal S, Alam A, Buse DC, Schwedt TJ, Lipton RB (2019) Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study. Cephalalgia 39(7):873\u2013882","journal-title":"Cephalalgia"},{"issue":"3","key":"1396_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1526-4610.2009.01544.x","volume":"50","author":"KM Sauro","year":"2010","unstructured":"Sauro KM, Rose MS, Becker WJ, Christie SN, Giammarco R, Mackie GF, Eloff AG, Gawel MJ (2010) HIT-6 and MIDAS as measures of headache disability in a headache referral population. Headache 50(3):383\u2013395","journal-title":"Headache"}],"updated-by":[{"DOI":"10.1186\/s10194-022-01422-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000}},{"DOI":"10.1186\/s10194-022-01434-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000}}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01396-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01396-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01396-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T17:41:12Z","timestamp":1726940472000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01396-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1396"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01396-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1175049\/v1","asserted-by":"object"}]},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,9]]},"assertion":[{"value":"16 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s10194-022-01422-y","URL":"https:\/\/doi.org\/10.1186\/s10194-022-01422-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s10194-022-01434-8","URL":"https:\/\/doi.org\/10.1186\/s10194-022-01434-8","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent. The study was approved by IRCCS San Raffaele Rome Ethical Committee n RP 19\/26, mutually recognized by the other local ethical committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Piero Barbanti received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Alder, Allergan, Angelini, Assosalute, Bayer, ElectroCore, Eli-Lilly, GSK, Lundbeck, Lusofarmaco, 1MED, MSD, New Penta, Noema Pharma, Novartis, Stx-Med, Teva, Visufarma, Zambon.Cinzia Aurilia received travel grants from FB-Health, Lusofarmaco, Almirall, Eli-Lilly Novartis and Teva;Gabriella Egeo received travel grants and honoraria from Eli-Lilly, Novartis, New Penta and Ecupharma;Florindo d'Onofrio received travel grant, honoraria as a speaker or for partecipating in advisory boards from Novartis, Teva, Neopharmed Gentili, Qbgroup srl, K link srl and Eli-Lilly.Maria Albanese received travel grants and honoraria from Novartis, Teva, Eli-Lilly and Lundbeck.Ilaria Cetta have no disclosures to declare.Paola Di Fiore\u00a0received honoraria as a speaker or for participating in advisory boards from\u00a0Novartis and Teva.Maurizio Zucco received travel grants and honoraria from Novartis.Massimo Filippi is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and\/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).Francesco Bono received honoraria as a speaker or for participating\u00a0in advisory boards from Teva, Novartis and Ipsen.Claudia Altamura received travel grants or honoraria for speaker panels from Eli-Lilly, Novartis, Teva, Lusofarmaco, Almirall, Laborest.S. Proietti have no disclosures to declare.S. Bonassi have no disclosures to declare.Fabrizio Vernieri received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Allergan, Eli-Lilly, Novartis, Teva, Amgen, Angelini and Lundbeck.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}